礼来口服减肥药可维持减重效果

Core Viewpoint - Eli Lilly (LLY) shares rose by 0.7% following the announcement of positive results from a Phase 3 clinical trial for orforglipron, which helps maintain weight loss in patients transitioning from injectable drugs Wegovy and Zepbound. The drug has been submitted for FDA approval and has received priority review status [1][2]. Group 1 - Eli Lilly's stock increased by 0.7% on Friday morning [1][2]. - The Phase 3 clinical trial demonstrated that orforglipron can help maintain weight loss effects after patients switch from Wegovy and Zepbound [1][2]. - The company has submitted orforglipron for FDA approval and it has been granted priority review status [1][2].